Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak

References

• WHO. Coronavirus disease (COVID-19) pandemic, numbers at a glance [website]. 2023 [updated 2023 Mar, 1; cited 2023 8 Mar]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
   Google Scholar
• Kertes J, Shapiro Ben David S, Engel-Zohar N, et al. Association between AZD7442 (tixagevimab-cilgavimab) administration and severe acute Respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality. Clin Infect Dis. 2023 Feb 8;76(3):e126–e132. doi: 10.1093/cid/ciac625
   PubMed Web of Science ®Google Scholar
• Sun J, Zheng Q, Madhira V, et al. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med. 2022 Feb 1;182(2):153–162. doi: 10.1001/jamainternmed.2021.7024
   PubMed Web of Science ®Google Scholar
• Lee A, Wong SY, Chai LYA, et al. Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022 Mar 2;376:e068632 doi: 10.1136/bmj-2021-068632
   PubMedGoogle Scholar
• Karaba AH, Kim JD, Chiang TP, et al. Omicron BA.1 and BA.2 neutralizing activity following pre-exposure prophylaxis with Tixagevimab plus cilgavimab in vaccinated solid organ transplant recipients. medRxiv. 2022 May 26.
   Google Scholar
• Wynia MK, Beaty LE, Bennett TD, et al. Real world evidence of neutralizing monoclonal antibodies for preventing hospitalization and mortality in COVID-19 outpatients. Chest. 2022;163(5): 1061–1070. doi: 10.1016/j.chest.2022.10.020
   PubMed Web of Science ®Google Scholar
• Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of covid-19. N Engl J Med. 2022 Jun 9;386(23):2188–2200. doi: 10.1056/NEJMoa2116620
   PubMed Web of Science ®Google Scholar
• NIH. COVID-19 treatment guideline. The National Institutes of Health. 2023 [updated 2023 Apr 20; cited 2023]. Available from: https://www.covid19treatmentguidelines.nih.gov/
   Google Scholar
• Bruel T, Hadjadj J, Maes P, et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med. 2022 Jun;28(6):1297–1302. doi: 10.1038/s41591-022-01792-5
   PubMed Web of Science ®Google Scholar
• Ordaya EE, Beam E, Yao JD, et al. Characterization of early-onset severe acute Respiratory syndrome coronavirus 2 infection in immunocompromised patients who received tixagevimab-cilgavimab prophylaxis. Open Forum Infect Dis. 2022 Jul;9(7):ofac283. doi: 10.1093/ofid/ofac283
   PubMed Web of Science ®Google Scholar
• Ocon AJ, Mustafa SS. Real-world experience of tixagevimab and cilgavimab (Evusheld) in rheumatologic patients on rituximab. J Clin Rheumatol. 2022 Sep 20;29(2):109–111 doi: 10.1097/RHU.0000000000001907
   PubMed Web of Science ®Google Scholar
• Conte WL, Golzarri-Arroyo L. Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters. Mult Scler Relat Disord. 2022 Jul;63:103905. doi: 10.1016/j.msard.2022.103905
   PubMed Web of Science ®Google Scholar
• Agency EM. Evusheld. [cited 2023 26 May]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/evusheld2023
   Google Scholar
• prevention Ccfdca. COVID-19 clinical and Surveillance data — December 9, 2022 to February 23, 2023, China https://weekly.chinacdc.cn2023 [ updated 2023, Mar 2; cited 2023 10, Mar]. Available from: https://weekly.chinacdc.cn
   Google Scholar
• Akinosoglou K, Rigopoulos EA, Kaiafa G, et al. Tixagevimab/Cilgavimab in SARS-CoV-2 prophylaxis and therapy: a comprehensive review of clinical experience. Viruses. 2022 Dec 30;15(1):118. doi: 10.3390/v15010118
   PubMed Web of Science ®Google Scholar
• Nguyen Y, Flahault A, Chavarot N, et al. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients. Clin Microbiol Infect. 2022 Dec;28(12):e1654 1–e1654 4. doi: 10.1016/j.cmi.2022.07.015
   Web of Science ®Google Scholar
• Young-Xu Y, Epstein L, Marconi VC, et al. Tixagevimab/Cilgavimab for prevention of COVID-19 during the Omicron surge: Retrospective analysis of national VA electronic data. mBio. 2022;14(4): e0102423. doi: 10.1128/mbio.01024-23
   Web of Science ®Google Scholar
• Leung K, Lau EHY, Wong CKH, et al. Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after adjustment of the zero-COVID policy in November–December 2022. Nat Med. 2023 Jan 13;29(3):579–582. doi: 10.1038/s41591-023-02212-y
   PubMed Web of Science ®Google Scholar
• Boschi C, Colson P, Bancod A, et al. Omicron variant escapes therapeutic monoclonal antibodies (mAbs) including Recently released Evusheld(R), contrary to 8 prior main variant of concern (VOC). Clin Infect Dis. 2022 Aug 24;75(1):e534–e535. doi: 10.1093/cid/ciac143
   PubMed Web of Science ®Google Scholar
• Stuver R, Shah GL, Korde NS, et al. Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell. 2022 Jun 13;40(6):590–591. doi: 10.1016/j.ccell.2022.05.007
   PubMed Web of Science ®Google Scholar
• Benotmane I, Velay A, Gautier-Vargas G, et al. Pre-exposure prophylaxis with 300 mg evusheld elicits limited neutralizing activity against the Omicron variant. Kidney Int. 2022 Aug;102(2):442–444. doi: 10.1016/j.kint.2022.05.008
   PubMed Web of Science ®Google Scholar
• Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022 Jul 7;387(1):86–88. doi: 10.1056/NEJMc2206576
   PubMed Web of Science ®Google Scholar
• Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022 Feb;602(7898):676–681. doi: 10.1038/s41586-021-04388-0
   PubMed Web of Science ®Google Scholar
• Kertes J, Gez SB, Saciuk Y, et al. Effectiveness of mRNA BNT162b2 vaccine 6 months after vaccination among patients in large health maintenance organization, Israel. Emerg Infect Dis. 2022 Feb;28(2):338–346. doi: 10.3201/eid2802.211834
   PubMed Web of Science ®Google Scholar
• Subramaniam A, Shekar K, Afroz A, et al. Frailty and mortality associations in patients with COVID-19: a systematic review and meta-analysis. Intern Med J. 2022 May;52(5):724–739. doi: 10.1111/imj.15698
   PubMed Web of Science ®Google Scholar
• Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023 Feb 8;76(3):e342–e349. doi: 10.1093/cid/ciac443
   PubMed Web of Science ®Google Scholar